Growth for the firm's core lab and pathology lab businesses was offset by a decline in molecular diagnostics and near patient care in the first nine months of the year.

The firm said it will develop a test for use at home and at the point of care to aid the diagnosis of syphilis and distinguish between active and past infections.

The Houston-based firm is set to scale up its Flu/Covid test manufacturing for the current respiratory virus season.

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

NEW YORK – The Advanced Research Projects Agency for Health (ARPA-H) announced on Wednesday $110 million in awards given to 23 commercial and academic entities as part of its Sprint for Women's Health ...

NEW YORK – Roche on Wednesday announced that for the first nine months of 2024 its diagnostics division revenues were essentially flat at CHF 10.73 billion ($12.36 billion) compared to CHF 10.68 ...

NEW YORK – Owlstone Medical has been developing a menu of breath-based tests using parallel approaches to detect in breath endogenous biomarkers of disease and measuring signals produced as the body ...